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1. Introduction 
Given that there is a wealth of literature on the potential effect of a wide variety of 
phytochemicals on the growth of prostate cancer cells, we have limited our discussion to 
arguably four of the most important: isoflavones, lycopene, resveratrol, and curcumin. The 
focus of this review is on the clinical pharmacology of these compounds, as there are 
already an extensive number of reviews in the literature on all of these compounds for 
various cancers, including our previous review of isoflavones in prostate cancer (de Souza et 
al., 2009). Here, we use the loose term “phytochemicals” to describe this group of plant–
based compounds with biological activity in vitro, for simplicity. Like other phytochemicals, 
isoflavones, lycopene, resveratrol and curcumin have a wide variety of potential 
mechanisms of action in many different cancer cell lines. Many of these biological effects 
involve key components of signal transduction pathways within cancer cells, but in this 
review, we will be focusing on studies specifically in prostate cancer. 
Reactive oxidative species (ROS) may have an overall contribution to the development of 
cancer (Kryston et al., 2011; Benhar et al., 2002), but the mechanism is far from clear, though 
the general thrust of the argument is that DNA damage wrought by ROS may be left 
unchecked or uncorrected by mismatch repair enzymes, thereby contributing to 
carcinogenesis (Benhar et al., 2002, Ziech et al., 2010, Kryston et al., 2011). However, it is also 
apparent that higher levels of ROS can activate intrinsic apoptosis (Benhar et al., 2002), 
which would imply that antioxidants should not be used indiscriminately as it could 
prevent a desirable outcome in cancer cells.  The biological mechanisms underpinning some 
of the potential anti-oxidant mechanisms of phytochemicals are complex and as yet 
speculative, and will not be discussed here. Instead, readers are referred to recent reviews 
(Ziech et al., 2010; Kryston et al., 2011). 
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Table 1 lists the major sources of our selected phytochemicals (Holden et al., 1999; Neveu et 
al., 2010; Nutrient Data, L. & Knovel, 2008; Tayyem et al., 2009), though we acknowledge 
that many other foods contain smaller amounts as well, though they are not reviewed here.   
 
Food 
Curcumin 
mg/100g 
Lycopene 
mg/100g 
Isoflavones 
mg/100g 
Resveratrol 
mg/100g 
Apricots, tinned  0.065   
Bilberry    0.67 
Chocolate, dark    0.04 
Cranberries, 
European 
   1.92 
Curry 50-580    
Grape, black    0.15 
Grapefruit, pink  1.3-1.5   
Guava, fresh  5.4   
Guava, juice  3.3   
Lingonberry    3.00 
Peanut   0.02 0.08 
Peanut butter   0.01 0.04 
Pistachio   3.6 0.11 
Red currant    1.57 
Soy paste, miso   41.4  
Soybean, 
tofu,firm 
  22.5  
Soybean,tofu, 
silken  
  30.0  
Strawberry    0.35 
Tomato, raw  3.0   
Tomato, boiled   4.4   
Tomato juice  9.3   
Tomato paste  6.5-29.3   
Tomato, sauce 
(ketsup) 
 17.0   
Tomato, tinned  9.7   
Turmeric 
powder 
580-3,140    
Wine, Red    0.27 
Wine, Rose    0.12 
Wine, White    0.04 
Table 1. Dietary sources of selected phytochemicals. 
2. Isoflavones 
Soy and soy products, rye bread, and red clover, are good sources of flavonoids 
(Adlercreutz, 2002). Flavonoids, in turn, are made up of isoflavones, flavonones, flavones, 
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flavonols, catechins, anthocyanins, and chalcones, of which the isoflavones are but a small 
part, though disproportionately studied. Isoflavone intake is approximately 50mg daily in 
Asia, about ten times more than in Western countries (Messina et al., 2006). 
2.1 Pharmacology 
There are many intermediates and metabolites of isoflavones produced in humans, but the 
majority have not been studied. Genistin, daidzin and glycitin are thought to be the 
predominant isoflavones found in soy foods, of which the glycoside moiety is the major 
form with anticancer activity. Through the action of  - glucosidase provided by gut 
bacteria, and hydrolysis, the conversion of glycosides to aglycones (Setchell et al., 2002; 
Yuan et al., 2007; Zubik & Meydani, 2003) allows absorption into the blood. One hypothesis 
for the variable absorption values obtained from studies is the variability of the gut 
microbacterial environment amongst humans. Some support for this concept was provided 
by Rufer et al., (2008), who gave pure daidzein in both its aglycone and glycoside forms to 
seven volunteer men in a randomized, double – blind study, at a dose of 1mg/kg. 
Bioavailability of the glycoside form was found to be 3-6 times higher than that of the 
aglycone form, with half – life measured at 6.4h for the glycoside and 8.9h for the aglycone. 
Given the differences recorded for maximum concentration (Cmax) and urinary excretion, it 
is not unreasonable to speculate that this observation could be explained by the time taken 
by gut microflora to generate metabolites. Inter - individual variability in pharmacokinetic 
parameters was very high for these metabolites, which clearly could not be explained by 
differences in pharmacogenomic factors, due to the randomized crossover design. 
There are few other pharmacokinetic reports of isoflavones and data are derived largely 
from single dose administration studies. In general, aglycones appear in the blood within 
two hours of ingestion (Atkinson et al., 2005; Franke et al., 1995; Richelle et al., 2002; Setchell 
et al., 2001). Peak plasma concentrations (Cmax) for aglycones occur at 4-7h, whereas the 
corresponding time for glycosides is 8-11h, implying that the rate limiting step for 
absorption is initial hydrolysis of the isoflavone (Setchell et al., 2001; Zubik & Meydani, 
2003). After about 48hrs, plasma concentrations are no longer detectable. In a study reported 
by Setchell et al., (2003), higher doses of isoflavones did not produce linear pharmacokinetic 
parameters, suggesting that uptake was rate - limiting and saturable. Administration of 
approximately 80mg isoflavones a day is thought to give concentrations of genistein and 
daidzein consistent with that found in patients on a high isoflavone diet (Howes et al., 2002). 
2.2 In vitro data 
The literature attests to a large array of potential biological effects of isoflavones, despite 
their similarity in chemical structure: genistein binds estrogen receptor better than daidzein 
(Kuiper et al., 1998) for example, and equol is more potent than daidzein in inhibiting 
prostate cancer cell growth (Hedlund et al., 2003). Genistein produces apoptosis in prostate 
cancer cells (Kyle et al., 1997), but it is also possible that low doses promote cancer cell 
growth while higher doses inhibit growth (Bergan et al., 1996). This apparently conflicting 
data is not limited to isoflavones, and if the potential biphasic effects of phytochemicals are 
true, the underlying mechanisms for this observation could represent an important area of 
future research.  
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Tyrosine kinase phosphorylation appears to be a key event influencing the fate of many 
cancer cells, and inhibition may increase apoptosis or inhibit prostate cancer cell growth. 
Some isoflavones appear to have this ability; for example, genistein has been shown to 
reduce FAK (focal adhesion kinase) activity just prior to apoptosis (Kyle et al., 1997).  It can 
also transiently activate the FAK : beta – 1 – integrin complex (Bergan et al., 1996; Liu et al., 
2000), which could theoretically help explain its ability to reduce metastases. Further, 
isoflavones may reduce activity of ERK1/2 and various cyclin dependent kinases (Agarwal 
et al., 2000). A range of other potential mechanisms for the growth inhibiting effects of 
isoflavones have been described (see Table 2).  
2.3 In vivo data 
Soy protein or biochanin A (another isoflavone) inhibits growth and increases apoptosis in 
the LNCaP prostate cancer xenograft model (Bylund et al., 2000; Rice et al., 2002). Dietary 
genistein supplementation can reduce the incidence of poorly differentiated 
adenocarcinoma in a transgenic strain of mice (Mentor-Marcel et al., 2001), and can improve 
survival. In a model where prostate cancer is induced by chemical carcinogens methyl 
nitrosourea (NMU) or 3,2-dimethyl-4-aminobiphenyl (DMAB) (Kato et al., 2000), soy protein 
or genistein can prevent growth (McCormick et al., 2007; Wang et al., 2002). Dose - response 
studies involving subcutaneously and orthotopically implanted tumours (Zhou et al., 1999; 
2002) demonstrated clear reduction of tumor growth with a variety of isoflavone 
preparations, though changes in a variety of biomarkers were not consistent, and depended 
on the type of isoflavone preparation. 
2.4 Clinical studies in prostate cancer 
An interesting study of 40 men randomized post-prostatectomy to a low fat / high 
isoflavone diet (Li et al., 2008) or a control diet showed lower 6 month IGF-1 concentrations 
in the treatment group.  Sera collected from treated patients were able to reduce in vitro 
growth of LNCaP cancer cells by 20%, suggesting biologically relevant concentrations were 
achieved. Soy has been shown to suppress growth of localized, but not for advanced disease 
(Kurahashi et al., 2007), perhaps not surprisingly, since prostate cancer is a heterogenous 
disease, and more advanced disease may have different underlying biology. 
Pharmacogenomic work suggests that the reduction in risk of prostate cancer may be 
positively associated with a greater ability to produce equol from other isoflavones (Akaza 
et al., 2002, 2004). “Nutrigenomic” factors may therefore play an important part in 
predicting those who might benefit from phytoestrogen supplementation (Steiner et al, 
2008). 
Many studies do not show evidence of benefit for isoflavones. One randomized, placebo-
controlled trial of 12 weeks treatment with genistein in men with early prostate cancer 
found no significant difference in PSA levels between the treatment and placebo groups 
(Kumar et al., 2004), although the authors suggested that surrogate measures were being 
affected by treatment. Other trials support the idea that isoflavones, even given over 
relatively short periods of time, can possibly slow the rate of rise of PSA, though no 
statistically significant conclusions can be drawn (Dalais et al., 2004; Hussain et al., 2003; 
Maskarinec et al., 2006; Pendleton et al., 2008). Even by administering high doses, up to 
600mg genistein daily, no statistically significant PSA changes were noted in a Phase I and  
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 Action References 
Androgen related functions 
5ǂ reductase a. Inhibited by genistein a. (Evans et al., 1995) 
PART-1 
a. Prostate androgen regulated 
transcript 1 inhibited by 
genistein and daidzein 
a. (Yu et al., 2003) 
 
AR 
a. Transcriptionally 
downregulated by genistein 
b. In LNCaP cells, Lycopene 
inhibited AR gene element in a 
dose response manner 
c. Resveratrol inhibits AR 
transcription activity in 
LNCaP 
d. Curcumin downregulates 
AR gene expression in 
androgen dependent and 
castration resistant prostate 
cancer cells 
a. (Davis et al., 2000; Takahashi 
et al., 2006; Tepper et al., 2007) 
b. (Zhang et al., 2010) 
c. (Wang et al, 2010) 
d. (Nakamura et al, 2002; Tsui 
et al., 2008) 
PSA 
a. mRNA expression and 
secretion reduced by genistein 
b. PSA mRNA not 
downregulated by lycopene in 
LNCaP 
c. Resveratrol downregulates 
expression in LNCaP cells  
d. Curcumin inhibits PSA 
expression 
a. (Davis et al., 2000; Rice et al., 
2007)  
b. (Peternac et al., 2008) 
c. (Hsieh & Wu, 2000; Mitchell 
et al., 1999) 
d. (Tsui et al., 2008) 
Cell survival and proliferation 
DNA synthesis 
b. Lycopene reduces DNA 
synthesis in primary cultures 
of prostate epithelia 
b. (Barber et al, 2006) 
Cyclins 
a. Cyclin B downregulated by 
genistein 
b. Lycopene downregulates 
cyclin D1  
c. C1/Cdk4 kinase and D1, E, 
B and cdk1 all downregulated 
by resveratrol in LNCaP lines; 
resveratrol increases cyclin A 
and cyclin E in LNCaP cells 
d. Curcumin downregulates 
cyclin expression 
a. (Davis et al., 1998)  
b. (Palozza et al., 2010) 
c. (Benitez et al., 2007; 
Kuwajerwala et al., 2002) 
d. (Aggarwal et al., 2009) 
 
Myt-1 
 
a. Upregulated by genistein a. (Touny & Banerjee, 2006) 
Wee-1 
 
a. Phosphorylation reduced by 
genistein 
a. (Touny & Banerjee, 2006) 
p21WAF1 
 
a. Upregulated by genistein 
c. Decreased by resveratrol in 
LNCaP 
d. Upregulated by curcumin  
a. (Davis et al., 1998; Lian et al., 
1998) 
c. (Benitez et al., 2007; 
Kuwajerwala et al., 2002; 
Mitchell et al., 1999) 
d. (Aggarwal et al., 2007) 
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p27Kip1 
 
a. Increased by genistein 
c. Upregulated by resveratrol 
in LNCaP only, not in PC-3 
cells; repressed by resveratrol 
in LNCaP cells 
d. Upregulated by curcumin 
a. (Bhatia & Agarwal, 2001; 
Kazi et al., 2003; Rice et al., 
2007) 
c. (Benitez et al., 2007; 
Kuwajerwala et al., 2002) 
d. (Aggarwal et al., 2007) 
Protein tyrosine kinase 
a. Inhibition of EGF tyrosine 
kinase activation by genistein 
c. Resveratrol inhibits tyrosine 
kinase 
d. Curcumin inhibits EGF-R 
signaling 
a. (Akiyama et al., 1987) 
c. (Sallman et al., 2007) 
d. (Dorai et al., 2000) 
PTEN 
a.Expression is induced by 
genistein and daidzein in PC3 
and LNCaP 
a. (Cao et al., 2006) 
  
Akt 
a. Inhibited by genistein 
b. Lycopene decreases AKT 
activation, leading to apoptosis 
in both androgen-responsive 
and independent PCa cells 
c. Inhibited by resveratrol 
d. Inhibited by curcumin; PI3K 
inhibited by curcumin 
a. (Bemis et al., 2004; Li & 
Sarkar, 2002; El Touny & 
Banerjee, 2007; Park et al., 
2005) 
b. (Ivanov et al., 2007) 
c. (Aziz et al., 2006; Chen et al., 
2010) 
d. (Yu et al., 2008; Shankar & 
Srivastava, 2007) 
mTOR 
a. Inhibited by genistein 
c. Resveratrol inhibits mTOR 
d. Inhibited by curcumin in 
PC-3 cells, 
a. (Rice et al., 2007) 
c. (Brito et al, 2009; Chen et al., 
2010) 
d. (Yu et al., 2008) 
MAPK 
a. MAPK inhibited by 
genistein 
b. Lycopene, at least partially 
inhibits MAPK 
c. MAPK is inhibited by 
resveratrol 
d. P38 is activated by 
curcumin in PC3 cells 
a. (Huang et al., 2005; Xu & 
Bergan, 2006) 
b. (Palozza et al., 2010) 
c. (Nguyen et al., 2008) 
d. (Hilchie et al., 2010) 
ERK1/2 
a. Inhibited by genistein; 
induced by isoflavones 
 
a. (Agarwal, 2000; Bhatia & 
Agarwal, 2001; Wang et al., 
2006; Wang et al., 2004)  
JNK 
a. Activation by genistein 
d. Activated by curcumin 
a. (Lazarevic et al., 2008) 
d. (Hilchie et al., 2010) 
NFκB 
a. Inhibited by genistein and 
soy isoflavones 
b. Downregulated by 
resveratrol   
a. (Davis et al., 1999; Li & 
Sarkar, 2002; Raffoul et al., 
2007; Singh-Gupta et al., 2009) 
b. ( Benitez et al., 2009) 
IGF-1/R 
a. Inhibition by genistein 
b. Lycopene decreases IGF-1R 
expression in PC-3 cells 
a. (Takahashi et al., 2006, 
Wang et al., 2003) 
b. (Kanagaraj et al., 2007) 
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STAT 
a. Activated by genistein 
c. Resveratrol inhibits Src and 
Jak kinases 
d. STAT 3 is inhibited by 
curcumin, but even more so by 
synthetic analogues of 
curcumin 
a. (Pinski et al., 2006) 
c. (Sallman et al., 2007) 
d. (Lin et al., 2009) 
TGFǃ 
a. TGFǃ inhibited by genistein 
d. IL6 induction via TGFǃ 
inhibited via curcumin 
a. (Xu & Bergan, 2006) 
d. (Park et al., 2003) 
Apoptosis 
Mdm2 
a. Downregulated by genistein 
d. mRNA reduced by 
Curcumin in a dose dependent 
manner 
a. (Li et al., 2005) 
d. (Li et al., 2007) 
Bax 
 
a. Increased by genistein 
b. Lycopene upregulates Bax 
in LNCaP 
c. Increased due to resveratrol 
in LNCaP 
d. Curcumin upregulates  
a. (Kazi et al., 2003) 
b. (Palozza et al., 2010) 
c. (Benitez et al., 2007) 
d. (Shankar & Srivastava, 2007) 
Bcl-XL 
a. Downregulated by genistein 
d. Down regulated by 
curcumin 
a. (Li et al., 2001) 
d. (Shankar & Srivastava, 2007) 
XIAP 
a. Inhibited by phenoxodiol in 
ovarian cancer cells and 
melanoma cells 
c. Resveratrol promotes 
interaction of XIAP with Bax to 
cause apoptosis 
d. Inhibited by curcumin 
a. (Alvero et al., 2006; Herst et 
al., 2007; Kamsteeg et al., 2003, 
Kluger et al., 2007; Sapi et al., 
2004)  
c. (Gogada et al., 2011) 
d. (Deeb et al., 2007) 
Caspases 
a. Activated and caspase 
inhibition overcome by 
phenoxodiol in HN12 cells; 
Caspase mediation by 
genistein induced apoptosis 
c. Resveratrol activates 
caspase: 9,6,7 and 3 leading to 
apoptosis 
d. In PC-3 cells, apoptosis 
caused by curcumin is 
independent of caspases; In 
LNCaP curcumin initiates 
caspase-dependent 
mitochondrial death  
a. (Aguero et al., 2005; 
Choueiri et al., 2006; Kumi-
Diaka et al., 2000; Kumi-Diaka 
& Butler, 2000) 
c. (Benitez et al., 2007) 
d. (Hilchie et al., 2010) PC-3 
results, 
(Shankar & Srivastava, 2007) 
LNCaP results 
Other targets 
HIF1ǂ 
a. Inhibition by genistein in 
PC3 cancer cells 
d. Curcumin inhibits gene 
transcription of HIF 1 alpha 
a. (Singh-Gupta, 2009) 
d. (Thomas et al, 2008) 
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VEGF 
a. Downregulated by genistein 
b. Inhibited by lycopene in 
xenografts  
c. Suppressed by resveratrol 
d. Inhibited by curcumin in 
LNCaP xenografts 
a. (Cao et al., 2006; Guo et al., 
2007; Li & Sarkar, 2002) 
b. (Yang, 2011) 
c. (Ganapathy et al., 2010) 
d. (Shankar et al., 2007) 
 
ERǃ 
a. Antagonist and partial 
agonist by genistein; 
expression reduced by 
genistein 
d. Estradiol binding inhibited 
by > 85% in PC-3 cells 
a. (Booth et al., 2006; Cao et al., 
2006; Kuiper et al., 1998; Pike 
et al., 1999; Wang et al., 2006 ) 
d. (Shenouda, et al., 2004) 
COX-2 
a. mRNA and protein 
expression reduced by 
genistein in LNCaP and PC3 
a. (Swami et al., 2009)  
Sphingosine Kinase 
a. Inhibited by phenoxodiol in 
endothelial cells 
c. Inhibited by resveratrol 
a. (Gamble et al., 2006)  
c. (Brizuela, 2010) 
TNOX 
a. Inhibited by phenoxodiol 
 
a. (Davies & Bozzo, 2006; 
DeLuca et al., 2005) 
Focal adhesion kinase 
a. Activity reduced by 
genistein 
a. (Kyle et al., 1997) 
Hypermethylation 
a. Reversal of DNA 
methyltransferase activity by 
genistein 
a. (Fang et al., 2007; Skogseth 
et al., 2005) 
MMP 
a. MMP2 and 9 downregulated 
by genistein; MMP2 
expression inhibited by 
phenoxodiol 
c. MMP3 and MMP9 
suppressed by resveratrol 
d. Curcumin inhibited 
expression of MMP2 and 
MMP9  
a. (Gamble et al., 2006; Huang 
et al., 2005; Kumi-Diaka, 2006; 
Li & Sarkar, 2002 ; Xu & 
Bergan, 2006) 
c. (Ganapathy et al., 2010) 
d. (Hong et al., 2006) 
 
Urokinase plasminogen 
activator 
a. Inhibited by genistein 
b. Lycopene upregulates UPA 
receptor 
a. (Jarred et al., 2002) 
b. (Forbes et al., 2003) 
Table 2. Selected molecular targets of phytochemicals in prostate cancer cells: (a), (b), (c), (d) 
refer to isoflavone, lycopene, resveratrol, and curcumin related literature, respectively. 
While many of these targets have been shown to be relevant in other cancer cell lines, here 
we have focused on publications on prostate cancer cell lines. 
pharmacokinetic study (Fischer et al., 2004), though serum dehydroepiandrosterone was 
reduced by 31.7% (P = 0.0004) at the end of the study, and estrogenic side effects were 
encountered. Biologically relevant concentrations of genistein, commensurate with in vitro 
activity, can be achieved with high doses of genistein - enriched isoflavone extracts 
(Takimoto et al., 2003). Peak plasma concentrations reached between 4.3 and 16.3uM at 
doses up to 8mg/kg orally (equivalent to 560mg for a 70kg person) in this study. 
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3. Lycopene  
Once water is reduced, the lycopene content of tomato products surpasses all other foods, 
weight for weight. Although lycopene melts at 172-173 degrees Celsius (Zapalis & Beck, 
1985), processing and cooking improves availability of tomato-sourced lycopene.  Being fat 
soluble, tomato sources of lycopene are best absorbed when cooked or consumed with a fat, 
such as with olive oil in Mediterranean cooking (Itsiopoulos et al., 2009).  As lycopene 
synthesis correlates with tomato ripening, it is older, vine ripened-in-the sun tomatoes that 
offer the highest lycopene content (Ronen et al., 1999). Other sources of lycopene, in 
descending order of content are: guava, watermelon, pink grapefruit (Mangels et al., 1993), 
apricots (Curl, 1960) and rosehips (Böhm et al., 2003).   
3.1 Pharmacology 
Lycopene is a non-provitamin A carotenoid. The frequency of light absorption, due to its 
alternating double bond system, defines visual color ranging from pink through to deep red. 
Once consumed, lycopene micelles are believed to be formed by bile salts and along with 
fat, pass from the mucosa and into general circulation via low-density lipoproteins (Sharma 
& Goswami, 2011). It is the only carotenoid associated with plasma cholesterol level 
(Campbell et al., 1994). Within the body, lycopene is preferentially stored in the liver, 
seminal vesicles and the prostate tissue.  In particular it becomes localized to the nuclear 
membrane and the nuclear matrix, suggesting that it may have a receptor or transporter 
role. In Western populations, blood lycopene concentrations range from 0.29-0.60 uM, with 
a half-life of 2-3 days (Schwedhelm et al., 2003). 
A Phase I single-dose study on lycopene pharmacokinetics using increasing doses from 10 
to 120 mg found dose dependent half-lives between 28 and 62 hours. Lycopene peaks 
between 16 and 33 hours after dosing levels of 0.075 to 0.21 uM (Gustin et al., 2004). 
3.2 In vitro data 
Like other phytochemicals, many potential mechanisms of action have been put forward to 
explain the anticancer properties of lycopene. Of relevance to prostate cancer, lycopene has 
been shown to inhibit DNA synthesis (Barber et al., 2006). Lycopene also inhibits growth of 
hormone-dependent LNCaP and C4-2 prostate cancer cell lines without affecting PSA 
mRNA expression (Peternac et al., 2008), and increases expression of PPARgamma and 
LXRalpha in LNCaP cells (Yang et al., 2011). It also inactivates Ras and reduces NFkappaB, 
as well as inducing apoptosis in LNCaP cells (Palozza et al., 2010). While it can reduce Akt 
activation (Ivanov et al., 2007), its ability to induce apoptosis may be cell line-dependent. 
Other potential mechanisms of action by lycopene in prostate cancer are listed in Table 2. 
In combination with docetaxel, lycopene inhibits growth of hormone independent prostate 
cancer DU145 cells through insulin-like growth factor 1 receptors leading to downstream 
inhibition of survivin expression and subsequent apoptosis (Tang et al., 2011). 
Almost certainly, variations in experimental conditions, doses and techniques could 
contribute to these apparent biological effects. At physiological concentrations, however, 
lycopene may not have growth inhibitory effects on a variety of cell lines (Burgess et al., 
2008). This was confirmed recently in experiments where supraphysiological concentrations 
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were required to reduce growth, possibly through alterations in the cell cycle (Ford et al., 
2011). 
3.3 In vivo data 
Athymic mice models used by Yang et al., (2011) show strong inhibition of PC3 xenograft 
growth by high doses of lycopene (16 mg/kg), possibly via increased levels of insulin-like 
growth factor-binding protein 3, or a reduction in plasma vascular endothelial growth factor 
(VEGF) levels. In a provocative study of androgen expressing prostate cancer cell lines 
treated with serum from rats fed a control diet, or diets supplemented with red, or yellow 
tomato (containing no lycopene), connexin43 (a protein regulating cell growth) was 
upregulated by both the red and yellow tomato supplemented diet (Gitenay et al., 2007). 
This suggests tomato compounds other than lycopene may have a role in reducing prostate 
cancer cell growth; one such candidate might be FruHis, a carbohydrate derivative found in 
tomato products (Mossine et al., 2008). However, in humans at least, dietary lycopene has 
been shown to affect gene expression, regardless of whether it is included in its food matrix 
(Talvas et al., 2010) 
In a transgenic mouse model, early intervention with selenium, vitamin E and lycopene 
supplements was able to significantly reduce prostate cancer and liver metastases 
(Venkateswaran et al, 2009). Limpens et al., (2006) had earlier reached the same conclusion, 
but they did not see any activity from the single agents. Naturally, it is difficult to know 
how much the additional supplements contributed to prostate cancer control, though both 
groups suggest the combination was important. Not all data are supportive of the growth 
inhibitory effect of lycopene however, possibly because of differences in the rat model used 
by Imaida et al., (2001). 
3.4 Clinical studies in prostate cancer 
Mills et al., (1989), through the Seventh Day Adventist men study, showed a link between 
low prostate cancer risk and frequent tomato consumption, along with beans, lentils and 
peas, raisins, dates, and other dried fruit. Giovannucci et al., (2007) performed an analysis 
on data from the Health Professionals study and found that higher tomato sauce (assumed 
to be lycopene) intake correlated inversely with prostate cancer incidence; indeed, this was 
only one of four factors (in addition to African American race, positive family history, and 
alpha-linolenic acid intake) that predicted for incidence and advanced prostate cancer. 
In a small, randomized trial of 30mg lycopene supplementation over 3 weeks prior to 
prostatectomy, margin positivity at surgery was reduced by lycopene, though no other 
endpoints were affected (Kucuk et al., 2001). The study was extremely small, and no 
conclusions can be drawn.  
Zhang et al., (2010) recently reported a study in 41 men with localized prostate cancer given 
10mg lycopene once a day. Seventy percent of men had a reduced slope of PSA rise, and 
21% had a decrease in their PSA levels. However, scant details were available for the study, 
and we do not know whether there were confounding variables; further, this would appear 
to be the same patient population as in a previous publication (Barber et al., 2006).  In a 
study of 41 men with localised prostate cancer (Barber et al., 2006) given 20 mg lycopene 
daily, nearly 70% of patients had a slower rate of PSA rise post-treatment. A study in 20 
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consecutive men with hormone refractory prostate cancer treated with lycopene 10mg daily 
had shown a response rate (complete and partial) of 35% (Ansari et al., 2004). However, this 
phenomenal response rate has not been able to be repeated. Indeed, Vaishampayan et al., 
(2007) reported a study in 38 men with hormone sensitive and resistant cancer randomized 
to the lycopene alone arm and found only PSA stabilization, without any patient qualifying 
for a partial response. Adding soy isoflavones (to men randomized to the other arm) did not 
appear to improve outcome. Another study in 46 patients with androgen-independent 
prostate cancer prescribed 15mg lycopene daily found only one patient with a PSA 
response; toxicity included mainly grade 1-2 diarrhea, nausea, flatulence, and abdominal 
distension (Jatoi et al., 2007). 
4. Resveratrol 
Resveratrol is a phytoalexin found in the skins and seeds of red grapes Vitaceaea vinifera. 
Therefore, red wines are especially rich in resveratrol, as is grape juice (Romero-Perez, 1999).  
Other sources include lentils (as resveratrol-3-O-glucoside), peanuts, dark chocolate and 
berries (Neveu, 2010). 
4.1 Pharmacology 
Resveratrol is well-absorbed, but has poor bioavailability due to extensive first pass 
metabolism by the liver. 
A pharmacokinetic study of trans-resveratrol (25, 50, 100 or 150mg  single doses, repeated 
over 13 dosings) showed Cmax detected 48 to 90 minutes post-dosing (Almeida et al., 2009), 
but there was wide interindividual variability reported, also noted in another 
pharmacokinetic study (Nunes et al., 2009).  In another study in 40 healthy volunteers given 
a single dose ten times the quantities used in the previous study (500, 1000, 2,500 or 
5,000mg), peak plasma concentrations were achieved in 90 minutes, and were associated 
with a range of plasma resveratrol concentrations between 73 and 539 ng/mL (Boocock et 
al., 2007).  Absorption may be faster after oral dosing (Goldberg et al., 2003), possibly due to 
delayed absorption by food (Vaz-da-Silva et al., 2008).  
Resveratrol is rapidly metabolized. Radioactively labeled carbon-14 distribution studies 
(Vitrac et al., 2003) have been performed in mice with trans-resveratrol; it distributes to the 
stomach, intestines, liver and kidney, regions of highest uptakes.  Mice, like men (de Santi et 
al., 2000 a,b,c) also form both sulfur and glucuronide conjugates, but a proportion remains 
unchanged as trans-resveratrol.  A toxicological study with trans-resveratrol (as resVida®) 
in rats over 4 weeks has tested up to 300 mg/kg/d, with no observed serious adverse events 
(Edwards et al., 2011). 
A phase I trial and repeated dose study to determine safety, pharmacokinetics and the effect 
on insulin-like growth factor (IGF) axis by resveratrol was recently reported (Brown et al., 
2010).  Doses of 0.5, 2.5 or 5.0 g per day over 29 days was given to forty volunteers. Levels of 
resveratrol metabolites in plasma were about 20 times higher than that of free resveratrol, 
and a reduction of circulating plasma IGF-1 and IGFBP-3 was noted (P< 0.04 in both).  It is 
not clear to what extent the metabolites contributed to the fall in plasma IGF-1 and IGFBP-3 
levels. 
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4.2 In vitro data  
Resveratrol results in dose-dependent inhibition of PI3K and pAkt in LNCaP cells that 
in turn modulates anti-apoptotic bcl2 family proteins (Aziz et al., 2006). Resveratrol 
reduces ERK 1/2 activation in PC3 cells (Stewart & O’Brian, 2004) amongst many other 
targets; some of these are listed in Table 2. For example, resveratrol also reduces the 
activity of clusterin by functioning as a tyrosine kinase inhibitor (Sallman et al., 2007), 
phosphoAkt and mTOR (Chen et al., 2010), and NFkB (Benitez et al., 2009). Resveratrol 
causes growth inhibition in typical prostate cancer cell lines: PC-3, DU145, and LNCaP 
(Hsieh & Wu, 1999), but interestingly, whole cranberry extract (containing resveratrol) 
was also effective in inducing apoptosis (Maclean et al., 2011). As in all whole-food 
extract studies, however, there is no certainty that the molecule of interest is responsible 
for the effect seen.  
4.3 In vivo data 
In a PC3 xenograft study, resveratrol alone inhibited tumour growth, enhanced TRAIL 
induced apoptosis, and inhibited angiogenenesis (Ganapathy et al., 2010). Resveratrol is also 
able to reduce or delay prostate cancer in the TRAMP mouse model (Slusarz et al., 2010), 
possibly via inhibition of HedgeHog signaling. Conflicting evidence was provided by Wang 
et al., (2008), who found that resveratrol increased angiogenesis and inhibited apoptosis, at 
least in LNCaP xenografts. 
4.4 Clinical studies in prostate cancer 
A review on clinical trials of resveratrol has already been recently published (Patel et al., 
2011), and will not be discussed in detail here. Selected prostate cancer trials are listed in 
Table 3. 
Resveratrol dosing studies have been performed at up to 5 grams per day.  However, mild 
gastrointestinal side effects (abdominal pain, nausea, diarrhea) were common in subjects 
administered resveratrol at a dose 1g daily (Brown et al., 2010; Elliott et al., 2009; la Porte et 
al, 2010). A Phase I study of resveratrol in 10 volunteers demonstrated that even at the 
highest 5 g per day cohort, saturation kinetics were not observed (Boocock et al., 2007) and 
that plasma concentrations remained quite low, 500 ng/mL. This possibly is considerably 
less that the 5uM concentration required for in vitro activity, but six plasma and urine 
metabolites were identified; whether these compounds contribute to the anticancer activity 
of resveratrol remains unknown. Two monoglucuronide metabolites of resveratrol area 
under the curve concentrations were 23-fold hold higher than that of cis-resveratrol 
(Boocock et al., 2007). Inter-individual pharmacokinetic variability has been found to be 
high (Almeida et al., 2009).   Complicating the picture is that other phytochemicals ingested 
in the diet, such as quercetin and to a lesser degree, kaempferol, fisetin, apigenin and 
myricetin, may inhibit phenol sulfotransferase and in doing so, increase resveratrol 
absorption (de Santi et al., 2000 a, b).  
As the studies in Table 3 have noted, data for resveratrol are not all favourable or 
particularly convincing. The reasons are not well understood, but could include ineffective 
plasma concentrations derived from inadequate doses, inter-individual pharmacokinetic  
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Intervention / Diet Design Outcome Reference 
Isoflavones    
 
N=34. Randomized 
crossover trial. 6 week 
intervention 
Reduced cholesterol but no 
change in PSA 
(Urban et al., 
2001) 
Single dose formulations 
of genistein, daidzein, 
glycitein 
Pharmacokinetic study 
Mean elimination half – lives of 
genistein was 3.2h and daidzein 
was 4.2h 
(Busby et al., 
2002) 
160mg daily of red clover 
isoflavone preparation 
(genistein, daidzein,  
formonetin,  biochanin A) 
N=38, pilot study of 
treatment prior to 
prostatectomy. 18 
treated vs 18 untreated 
patients. Non – 
randomized and non – 
blinded study 
Apoptosis in treated patient 
specimens significantly higher 
than controls. No changes in 
PSA, testosterone. 
(Jarred, 2002) 
Soy isoflavone 
preparation for 3 – 6 
months 
N=41, Pilot study in 3 
groups (watchful 
waiting, rising PSA after 
local therapy, hormone 
insensitive) 
Reduction of rate of rise of PSA 
in whole group. Serum 
genistein concentrations 
increased from 0.11 to 0.65µM 
and daidzein from 0.11 to 
0.51µM.  PSA stabilization in 
83% of hormone sensitive group 
and 35% hormone insensitive 
patients 
(Hussain et al., 
2003) 
Single doses of two soy 
isoflavone preparations 
N=13. Phase I dose 
escalation with genistein 
at 2, 4, 8mg/kg. 
Cmax between 4.3 and 16.3µM, 
half – life between 15 and 22h. 
(Takimoto et al., 
2003) 
Approximately 300mg or 
600mg genistein and 
daidzein in soy 
formulation 
N=20. Phase I multiple 
dose, orally over 84 days 
31% reduction in 
dehydroepiandrosterone. 
Possibly slowing of PSA  rise 
(non – significant) 
(Fischer et al., 
2004) 
Soy vs Soy + linseed vs 
wheat in bread diet 
N=29, Pilot study. 
randomized comparison 
prior to prostatectomy 
-12% and 24% change in PSA 
and free/total ratio respectively. 
In favour of phytoestrogen 
activity. 
(Dalais et al., 
2004) 
Genistein – rich extract 
for 6 months 
N=62, range of rising 
PSA states including 
post – prostatectomy, off 
cycle during 
intermittent hormones, 
surveillance. 
One patient had PSA decline 
>50% and 8 patients had PSA 
decline <50%. 
(de Vere White 
et al., 2004) 
60mg soy isoflavone 
preparation 
N=59 evaluable patients 
who completed 12 
weeks treatment. 
Gleason grade 6 or less. 
Reduction of testosterone in 61% 
of treatment group vs 33% of 
controls. PSA stabilization in 69% 
of treatment group vs 55% 
controls. 
(Kumar et al., 
2004) 
Supplement of soy, 
isoflavones, lycopene, 
silymarin, antioxidants 
N=46 (intent to treat). 
Randomized, double 
blind, crossover 
analysis. 10 week 
treatment periods 
separated by 4 week 
washout  
Statistically significant 
reduction in slope of PSA 
induced by treatment. Increase 
in PSA doubling time from 445 
to 1150 days (2.6 fold) with 
supplement 
(Schroder et al., 
2005) 
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Intervention / Diet Design Outcome Reference 
240mg clover 
phytoestrogens daily for 
2 weeks prior to 
prostatectomy 
N=20, pilot study, 
placebo controlled. 
Non – significant decline in 
testosterone levels, but 
compensated rise in LH levels 
(Rannikko et al., 
2006) 
High or low soy diet for 3 
months 
N=24, randomized 
crossover to alternative 
diet after 1 month 
washout 
Decline of PSA (not significant) 
of 14% while on high soy diet 
(Maskarinec et 
al., 2006) 
Lycopene with or without 
soy isoflavones for 6 
months 
N=71, includes hormone 
sensitive and resistant 
patients. Randomized 
trial. 
95% of patients in lycopene 
group and 67% of patients in the 
combined group achieved PSA 
stabilization. 
(Vaishampayan 
et al., 2007) 
80mg daily, purified 
isoflavones 
N=50 men with prostate 
cancer Gleason grad 6 or 
less completed 
treatment. Randomized, 
placebo controlled, 
double blind 
No changes in sex hormones or 
PSA over 12 weeks 
(Kumar et al., 
2007) 
Soy milk 3 times daily for 
12 months 
N=20, open label study 
observing rate of PSA 
rise after local therapy 
Regression modeling showed 
slowing of the rate of PSA rise, 
from 56% per year to 20% per 
year while on study 
(Pendleton et al., 
2008) 
Soy isoflavone 
supplement for 2 -4 
weeks prior to 
prostatectomy 
N=25 (12 placebo, 13 
soy). Randomized, 
double blind, placebo 
controlled 
Tissue COX-2 mRNA 
expression were reduced by soy 
isoflavones. Statistically 
significant correlation between 
isoflavone levels and p21 
mRNA expression in the 
treatment group. 
(Swami et al., 
2009) 
Soy vs Soy + linseed vs 
wheat in bread diet 
N=29, Pilot study. 
randomized comparison 
prior to prostatectomy 
-12% and 24% change in PSA 
and free/total ratio respectively. 
In favour of phytoestrogen 
activity. 
(Dalais et al., 
2004) 
Lycopene    
 15 mg Lycopene daily for 
6 months 
N=18, Phase II pilot study 
in men with advanced 
hormone refractory 
disease. 29% withdrew 
from the study before the 
end of the 6 month 
observation period. 
 Endpoints included PSA 
progression rate, QOL, 
analgesic use. Stable PSA noted 
in 29%, but otherwise 
no benefit. 
(Schwenke, et 
al., 2009) 
30 mg/d lycopene 
supplement tomato 
oleoresin (LycoRed®) 
 
N=105. Randomized 
Phase II, placebo 
controlled, double blind 
study in African 
Americans. 21 day 
treatment prior to 
prostate biopsy.  
 
Mean Plasma lycopene 
concentration 0.74 to 1.43 
µmol/L (P<0.0001),  
Mean Prostate tissue lycopene 
0.45 to 0.59 pmol/mg. No 
significant changes in 8-oxo-
deoxyguanosine or 
malondialdehyde was seen. 
(van Breemen et 
al., 2011)  
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Intervention / Diet Design Outcome Reference 
3 months of 30mg 
lycopne per day, 3g fish 
oil per day, or placebo 
N = 69 (22 on lycopene,  
21 on fish oil, 26 
placebo). Randomized, 
Phase II double-blind 
trial. 
IGF-1 and COX-2 gene 
expression did not change 
compared to placebo in men 
with early stage, low grade 
prostate cancer. 
(Chan et al., 
2011) 
10mg daily for 3 months 
N=20, metastatic 
hormone refractory 
prostate cancer 
One patient (5%) with complete 
response, 6 with partial 
response (30%) 
(Ansari & 
Gupta,2004) 
10mg daily 
N=41, localized prostate 
cancer on surveillance 
Regression slopes of (log) PSA 
vs time decreased in 
26/37 (70%, 95% CI: 53–84%) of 
the patients after 
supplementation 
and in eight cases (21%) the 
post-treatment 
slope was negative 
(Barber et al., 
2006) 
15mg, 30mg, or 45mg for 
30 days 
N=45, randomized to 
one of 3 doses of 
lycopene prior to 
prostatectomy 
No toxicity, but reduced serum 
free testosterone and increased 
total estradiol was noted. 
(Kumar et al., 
2008) 
Resveratrol    
Trans-resveratrol at: 
0, 25,50,100 and 150 mg,  
6 times/d for 13 doses-  
Double blind, 
randomized, placebo 
controlled Healthy 
volunteers,  
N=40, as 4 x 10 per 
group 
5 males 
Phase I 
 
Mean plasma concentration was 
3.9, 7.4, 23.1 and 63.8 ng/mL 
and peaked in 0.8-1.5 hours post 
dose:  Mean area under curve 
for plasma, post the 13th dose 
was 3.1, 11.2, 33.0 and 78.9 
ng/mL; coefficients of variation 
>40%  
Adverse events were mild and 
similar between groups, but low 
plasma concentrations achieved 
(Almeida, et al., 
2009) 
2 g resveratrol BID over 8 
days 
N=8 Healthy subjects 
Steady state and 
pharmacokinetics study 
Tolerability with food, 
quercetin and alcohol 
Phase I 
6/8 has loose stool or mild 
diarrhea at the start of the study 
1 subject developed rash and 
headache 
(la Porte et al., 
2010) 
 
Up to 975 mg/d as: 
25,50,100,150 mg given 6 
times per day over 2 days 
N=8 Healthy volunteers 
Double blind 
Randomized 
Placebo-controlled 
Phase I 
4 men, one per dosing 
level 
Mild adverse events experience 
d; low plasma concentrations 
achieved 
(Almeida  , 2009) 
28 day x 36 µg resveratrol 
per day- as Chardonnay 
cava wine containing 
trans-resveratrol, cis-
resveratrol, and cis-piceid  
Healthy volunteers 
Phase I 
Decrease in inflammatory 
markers: 
 IL-6, high sensitivity CRP, 
intercellular adhesion molecule-
1 (ICAM-1), monocyte chemo 
attractant protein 1 (MCP-1)  
(Soleas et al., 
2002) 
270 mg/d resveratrol 
over 7 days 
N=19 
Phase I 
“did not cause discomfort” 
(Wong et al., 
2010) 
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Intervention / Diet Design Outcome Reference 
2.5 versus 5 g per day for 
28 days 
N = Healthy volunteers 
Phase I 
Mild and reversible AEs 
(Elliott et al., 
2009) 
Single resveratrol doses 
of 0.5, 1, 2.5 and 5 g using 
500 mg capsules 
Healthy volunteers 
10/level = 40 
Pharmacokinetic study 
and metabolite 
6 metabolites found in urine 
and plasma 
No serious adverse events 
Peak Plasma 539 ng/mL 1.5 
hour post dose, peak AUC for 
metabolites were up to 23 time 
that of resveratrol, rapid urinary 
excretion. 
(Boocock et al., 
2007) 
25mg to 5 g resveratrol 
 
 
Dose escalation  
Phase I  
40 Healthy volunteers 
No evidence of saturation with 
a continuing linear response- 
very limited plasma 
concentrations, at high 5 g 
intake only 500 ng/mL levels 
achieved  
(Boocock et al., 
2007a,b)  
 
500 mg caps resveratrol 
At 0.5, 1, 1.25 or 5.0 g 
once daily over 29 days 
 Healthy adults 
22 Males, 18 Females 
Safety, 
Pharmacokinetics  
Phase I 
Lower IGF-1 and IGFBP-3 in 
plasma.In all ,28/40 healthy 
adults had at least one adverse 
event,:  nausea, diarrhea or 
abdominal pain, all above 1 g 
daily 
(Brown et al., 
2010) 
Curcumin    
Soy isoflavones (40mg) + 
Curcumin (100mg) or 
placebo for 6 months 
Randomised trial, N=85 
men who had previous 
prostate biopsies but 
were negative for cancer 
and PIN. 
PSA reduction was greater in 
subgroup of men who had 
higher baseline PSA value, but 
overall, there was no statistical 
difference between those who 
had supplements and those on 
placebo 
(Ide et al., 2010) 
Table 3. Selected clinical trials of phytochemicals in prostate cancer. 
and pharmacodynamic variability, and other factors such as drug interaction. For example, 
resveratrol has been shown to inhibit cytochrome P 450; 3A4, 2D6, 2C9 and alternately 
induce 1A2 (Chow et al., 2010), a key factor that has not been taken into account in many 
clinical studies. Theoretically, interactions with concomitant medications whilst on trial may 
therefore result in either unwanted toxicity or reduced concentrations of resveratrol. 
5. Curcumin 
Curcumin is only found as an active component of whole or ground turmeric, within the 
rhizome or root nodule, specifically of two branches of the ginger family, Zingiberaceas, of 
the species, Curcuma longa Linneas, Curcuma aromatica or Curcuma zantorrhiza and in tropical 
ginger, Zingiber cassumaunar.  In India, turmeric in dried curry powders range considerably 
from 10 to 32% (Govindarajan, 1980). 
5.1 Pharmacology 
Structurally, curcumin (diferuloylmethane, a polyphenolic molecule) is a diketone and can 
also be classified as a phenylpropanoid. It is known to have poor solubility and poor 
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bioavailability (Anand et al., 2007).  Absorption and transformation occurs at the intestinal 
wall, where enzymes such as sulfotransferases, UDP-glucoronyltransferase, and P450 ensure 
its rapid breakdown (Ireson et al., 2002). Pharmacokinetic studies, including Phase I and 
other trials confirm the poor bioavailability of the compound (Cheng et al, 2001; Sharma et 
al., 2004; Garcea et al., 2005; Garcea et al., 2004). Data from these studies show that curcumin 
seems to be absorbed from the gut within 1-2hrs, and doses up to 8000mg have produced 
minimal toxicity. Nausea and diarrhea have been the principal toxicities encountered. 
Vareed et al (2008) studied doses of either 10g or 12g in volunteers, and found Cmax to be 
around 1.7-2.3 ug/mL, with time taken to reach maximum concentration (Tmax) and half-
life estimated to be 3.3h and 6.8h, respectively. Sharma et al., (2004) studied escalating doses 
in a Phase I trial up to 3.6g daily and found no dose-limiting toxicity. Mild nausea and 
diarrhea was encountered, but plasma concentrations of only around 10nM could be elicited 
in this study; nevertheless, inducible PGE2 production was reduced by about 50-60% at that 
dose level. 
5.2 In vitro data  
There is a wealth of literature on the potential mechanism of action of curcumin in vitro (see 
Table 2), but it is not clear which is the predominant mode of action. It is highly likely that 
different mechanisms of action exist for different cell lines. Curcumin can inhibit Akt and 
mTOR in PC3 cell lines (Yu et al., 2008), and enhance Apo2L/TRAIL induced apoptosis, at 
least in ovarian cancer cells (Wahl et al., 2007). EF24, a curcumin analogue, and curcumin 
itself can inhibit HIF1alpha gene transcription in PC3 prostate cancer cells (Thomas et al., 
2008). Teiten et al., (2011) showed that curcumin induced cell cycle arrest in G2 phase and 
could modulate Wnt signaling in androgen-dependent prostate cancer cells, but not in 
androgen-independent cells. 
Apoptotic and growth inhibitory pathways are affected by curcumin in numerous ways 
(Ravindran et al., 2009). One example is its ability to abrogate survival mechanisms via 
suppression of constitutive and inducible NF-kappaB activation (Mukhopadhyay et al., 
2001). It can also induce apoptosis of DU145 and LNCaP, associated with reduction of 
expression of Bcl2 and bcl-xL (Mukhopadhyay et al., 2001). 
5.3 In vivo data 
Curcumin inhibits LNCaP xenograft growth, induces apoptosis, and sensitizes tumours to 
TRAIL induced apoptosis (Shankar et al., 2007). Others have also demonstrated the growth 
inhibitory properties of curcumin in vivo (Barve et al., 2008; Khor et al., 2006), possibly via 
antiangiogenic mechanisms such as reduction of MMP-2 and MMP-9 expression (Hong et 
al., 2006). Liposomal encapsulation of curcumin, particularly in combination with 
resveratrol, significantly reduces prostate cancer tumours in vivo (Narayanan et al., 2009). 
5.4 Clinical studies 
Despite the intense interest in curcumin as a possible cancer prevention agent, there is a 
surprising lack of clinical data in prostate cancer. Efforts have focused on improving 
bioavailability by incorporating curcumin in nanoparticles, or developing more potent 
analogues. Whilst ongoing trials in prostate cancer are yet to be reported, the only trial we 
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could find described a randomized study of the combination of soy isoflavone and 
curcumin compared to placebo in men who did not have prostate cancer after undergoing 
prostate biopsy (Ide et al., 2010); its relevance for prostate cancer can therefore be 
questioned. 
6. Studies on the the combination of phytochemicals and androgen ablation 
Even though androgen suppression for metastatic disease is effective treatment, invariably, 
castrate resistance develops. However the recent development of new drugs that act on the 
androgen receptor (AR) suggest that there is still a role for androgen manipulation beyond 
the point traditionally defined as “castration resistance”. As a result, there is renewed 
interest in whether phytochemicals modulate androgen receptor function in prostate cancer. 
It appears each phytochemical discussed in this review accomplishes androgen receptor 
inhibition, but all may use different mechanisms. For example, isoflavones have been shown 
to reduce androgen receptor transcription (Gao et al., 2004), and down regulate prostate 
androgen-regulated transcript-1 gene expression (Yu et al, 2003), whereas androgen receptor 
gene element is inhibited by lycopene in a dose-dependent manner in studies with LNCaP 
cells (Zhang et al., 2010). Lycopene appears to interact with AR by affecting ǃ-catenin 
nuclear localization and inhibiting IGF-1 stimulated prostate cancer growth (Kucuk et al., 
2002; Liu et al 2008). Resveratrol functions include the inhibition of androgen receptor 
transcription activity (Wang et al., 2010; Shi et al 2009) and down regulation of PSA 
expression (Mitchell at al, 1999; Hsieh & Wu, 2000) as tested in LNCaP cell lines. Others 
have shown that it also inhibits DNA binding of androgen receptor (Harada et al., 2011). 
Finally, androgen receptor function is inhibited by curcumin in LNCaP (Tsui et al., 2008) 
and in PC3 (Nakamura et al., 2002) cell lines. Curcumin appears to down regulate 
transactivation and expression of AR and AR-related cofactors, including activator protein-1 
(AP-1), NF-kB, and cAMP response element binding protein (CREB) (Nakamura et al.,  
2002). 
Burich et al., (2008), showed that the combination of genistein combined polysaccharide 
(GCP) and bicalutamide had enhanced activity against LNCaP and LNCaPR237H cell lines. 
Presumably, the basis of synergistic activity observed was the ability of GCP to 
downregulate AR and suppress mTOR (Tepper et al., 2007). 
7. Studies on the combination of phytochemicals and chemotherapy 
In many clinical studies, the possibility that something other than the phytochemical of 
interest, obtained from the diet, may influence outcome has probably not been given 
sufficient weight in the literature. Given that foods contain many phytochemicals other than 
those proposed to have anti-cancer activity, it is surprising to find little work on the 
potential synergistic or antagonistic interactions between different phytochemicals on cancer 
cell lines. Further, since many experiments involve unspecified doses, sources and contents 
of phytochemicals, it is not possible to conclude whether true synergistic growth inhibition 
occurs when these agents are used in combination. 
Synergy or enhanced activity has been reported in prostate cancer cell lines using 
isoflavones in combination with paclitaxel (Ping et al., 2010), radiation (Raffoul et al., 2007), 
and docetaxel (Burich et al., 2008). Phenoxodiol, a novel isoflavone, in combination with 
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cisplatin has been shown to be synergistic against DU145 cells and probably additive in PC3 
cells (McPherson et al., 2009). In vivo combination therapy of soy isoflavones and radiation 
for prostate cancer has also been investigated, with favorable effects on the control of the 
disease (Raffoul et al., 2007; Wang et al., 2006). 
Docetaxel effect in castration-resistant prostate cancer patients was improved by lycopene 
via insulin-like growth factor 1 receptor perturbation (Tang et al., 2011). Using an animal 
model to confirm these findings, a 38% improvement over docetaxel was found (P=0.047). 
Lycopene appeared to work by inhibiting IGF-1 stimulation and increasing expression and 
secretion of IGF-BP3.  Downstream effects included reduced AKT kinase activity and 
survivin production and increased apoptosis. 
Resveratrol enhances ionizing radiation - induced cell death in DU145 cells, which are 
thought to be relatively radiation-resistant (Scarlatti et al., 2007), and as previously noted, 
enhances TRAIL-induced apoptosis in vivo (Ganapathy et al., 2010). Radiosensitisation 
properties, at least in PC3 cells, also appear to belong to curcumin (Chendil et al., 2004; Li et 
al., 2007), and like resveratrol, curcumin also enhances TRAIL-induced apoptosis in prostate 
cancer cells (Deeb et al., 2005). Synergy between curcumin and a number of cytotoxic agents 
including doxorubicin, 5FU and paclitaxel occurs in PC3 and DU145 cells (Hour et al., 2002), 
as well as gemcitabine in PC3 (Li et al., 2007). 
The advantage of finding synergy lies in an increased benefit: risk ratio if compounds being 
combined are more effective (synergistic) without necessarily being more toxic, particularly 
if they are known to be well-tolerated as single agents. Further, because some 
phytochemicals have poor bioavailability, the discovery of synergistic interactions with 
other phytochemicals in prostate cancer gives rise to the hypothesis that therapeutic effects 
may be obtained from a variety of combinations, even though individual phytochemicals 
may have questionable clinical effect. 
8. Conclusions  
The literature surrounding the idea of using phytochemicals for the prevention of prostate 
cancer is considerable, yet there are disproportionately few clinical studies, and just about 
none that show a convincing effect for biological outcomes in a clinical setting. Showing 
meaningful outcomes in a prostate cancer prevention trial with phytochemicals would 
ideally involve a prospective, randomized, placebo controlled trial that would require large 
numbers of patients to provide statistical power. Given that prostate cancer patients can live 
for many years, long-term follow up, is also required. Both of these requirements make such 
studies extremely difficult to mount. Nevertheless, many have investigated the effect of 
phytochemical administration in men with established prostate cancer (see Table 3). The 
lack of standardization in endpoints (eg. PSA, sex hormone changes) means that drawing 
systematic conclusions from such data is problematic, if not impossible. Other flaws in these 
studies include short-term administration of the phytochemical in question, highly variable 
sources, preparations and combinations, underpowered studies, and almost certainly 
inadequate dosing and scheduling of these compounds. However, the wealth of preclinical 
literature concerning the potential use and mechanisms of action of phytochemicals for 
prostate cancer will no doubt continue to provide impetus for therapeutic trials for some 
time to come. There are some serious pharmacological challenges in simply administering a 
www.intechopen.com
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single agent though, and it remains to be seen whether new approaches such as developing 
analogues of phytochemicals, or improving their bioavailability through better formulations 
will ultimately prove successful.  
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